يعرض 1 - 10 نتائج من 10 نتيجة بحث عن '"Triple Negative Breast Neoplasms drug therapy"', وقت الاستعلام: 1.31s تنقيح النتائج
  1. 1

    المصدر: Coe, F, Misra, V, McCabe, Y, Adderley, H, Woodhouse, L, Ayub, Z, Wang, X, Howell, S & Ekholm, M 2022, ' Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer ', Breast Cancer Research and Treatment, vol. 191, no. 3, pp. 535-543 . https://doi.org/10.1007/s10549-021-06438-7

  2. 2

    المصدر: Cancer Letters, Vol. 449 (2019) pp. 45-55
    Cancer letters, vol. 449, pp. 45-55

    وصف الملف: application/pdf

  3. 3

    المصدر: Scientific Reports, Vol. 7, No 1 (2017)
    Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
    Scientific Reports
    Scientific reports, vol. 7, no. 1, pp. 11964

    وصف الملف: application/pdf

  4. 4

    المصدر: Annals of oncology, vol. 27, no. 8, pp. 1525-1531
    Annals of Oncology

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Receptor, ErbB-2, Phases of clinical research, Triple Negative Breast Neoplasms, chemistry.chemical_compound, 0302 clinical medicine, Breast Tumors, Anthracyclines, Neoplasm Metastasis, eribulin, Triple-negative breast cancer, Randomized Controlled Trials as Topic, media_common, education.field_of_study, clinical trial, Hematology, Ketones, Metastatic breast cancer, 030220 oncology & carcinogenesis, triple-negative breast cancer, Female, Taxoids, metastatic breast cancer, pooled analysis, Eribulin, Bridged-Ring Compounds, Eribulin Mesylate, medicine.medical_specialty, Population, Antineoplastic Agents, survival, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, media_common.cataloged_instance, European union, Adjuvants, Pharmaceutic, Anthracyclines/adverse effects, Anthracyclines/therapeutic use, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Bridged-Ring Compounds/administration & dosage, Bridged-Ring Compounds/adverse effects, Clinical Trials, Phase III as Topic, Furans/adverse effects, Furans/therapeutic use, Ketones/adverse effects, Ketones/therapeutic use, Receptor, ErbB-2/antagonists & inhibitors, Receptor, ErbB-2/genetics, Taxoids/administration & dosage, Taxoids/adverse effects, Triple Negative Breast Neoplasms/drug therapy, Triple Negative Breast Neoplasms/genetics, Triple Negative Breast Neoplasms/pathology, Furans, education, Taxane, business.industry, Original Articles, medicine.disease, 030104 developmental biology, chemistry, business

    وصف الملف: application/pdf

  5. 5

    المصدر: Christensen, A G, Ehmsen, S, Terp, M G, Batra, R, Alcaraz, N, Baumbach, J, Noer, J B, Moreira, J M A, Leth-Larsen, R, Larsen, M R & Ditzel, H J 2017, ' Elucidation of altered pathways in tumor-initiating cells of triple-negative breast cancer : A useful cell model system for drug screening ', Stem Cells, vol. 35, no. 8, pp. 1898–1912 . https://doi.org/10.1002/stem.2654

  6. 6
    مورد إلكتروني

    المصدر: Nature communications, 14 (1

  7. 7
    مورد إلكتروني

    المصدر: Polk , A , Svane , I-M , Andersson , M & Nielsen , D 2018 , ' Checkpoint inhibitors in breast cancer - current status ' , Cancer Treatment Reviews , vol. 63 , pp. 122-134 .

    URL: https://curis.ku.dk/portal/da/publications/checkpoint-inhibitors-in-breast-cancer--current-status(0ef7b96c-9c64-4a34-aaca-ff8d39e0f0c1).html
    https://doi.org/10.1016/j.ctrv.2017.12.008

  8. 8
    مورد إلكتروني

    المصدر: European radiology, 26 (5

  9. 9
  10. 10